Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 02.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ 1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
Stammdaten
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Unternehmen & Branche
| Name | GeoVax Labs, Inc. |
|---|---|
| Ticker | GOVX |
| CIK | 0000832489 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 996.808 USD |
| Beta | 3,81 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -21,464,771 | 6,341,868 | 3,825,132 | ||
| 2025-09-30 | 10-Q | -6,318,914 | 6,731,255 | 4,907,078 | ||
| 2025-06-30 | 10-Q | -5,369,783 | 5,350,420 | 2,821,196 | ||
| 2025-03-31 | 10-Q | -5,357,651 | 10,833,364 | 7,898,030 | ||
| 2024-12-31 | 10-K | -24,992,296 | 8,155,867 | 5,048,535 | ||
| 2024-09-30 | 10-Q | -5,815,468 | 11,112,048 | 8,503,876 | ||
| 2024-06-30 | 10-Q | -5,064,042 | 4,095,070 | -2,309,226 | ||
| 2024-03-31 | 10-Q | -5,850,132 | 3,358,182 | 54,275 | ||
| 2023-12-31 | 10-K | -25,966,762 | 9,283,219 | 5,763,338 | ||
| 2023-09-30 | 10-Q | -8,408,818 | 16,201,031 | 9,119,346 | ||
| 2023-06-30 | 10-Q | -5,927,620 | 21,249,062 | 17,163,550 | ||
| 2023-03-31 | 10-Q | -4,037,916 | 27,404,212 | 22,865,157 | ||
| 2022-12-31 | 10-K | -14,021,125 | 31,347,928 | 26,600,034 | ||
| 2022-09-30 | 10-Q | -3,968,102 | 38,570,444 | 31,781,039 | ||
| 2022-06-30 | 10-Q | -2,241,699 | 33,240,525 | 27,872,657 | ||
| 2022-03-31 | 10-Q | -2,427,515 | 16,854,755 | 11,353,652 | ||
| 2021-12-31 | 10-K | -18,570,317 | 11,797,064 | 4,361,704 | ||
| 2021-09-30 | 10-Q | -1,950,503 | 18,339,500 | 18,003,850 | ||
| 2021-06-30 | 10-Q | -1,314,033 | 19,817,360 | 19,458,338 | ||
| 2021-03-31 | 10-Q | -1,562,778 | 21,115,446 | 20,651,340 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | SPENCER JOHN N JR | Director | Open Market Purchase | 10,000 | 0.55 | 5,498.00 | +176,2% | |
| 2025-08-07 | McKee Kelly T. Jr. | Officer, Chief Medical Officer | Open Market Purchase | 1,107 | 0.67 | 741.69 | +23,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.